Insights

Patient monitoring is an inherent part of patient management. Intermittent and continuous measurements have a range of uses, from defining disease states and characterising progression to informing therapeutic approaches and...

Clinical trials are vital for informing pharmaceutical companies about drug action and efficacy, and for demonstrating the safety of new drugs. However, they can be notoriously expensive, time-consuming to conduct, and the commercial...

The recent launch of the Apple Watch Series 4 is the latest example of a device developed by a traditional consumer product company making a well-publicized entry into the patient-facing medical device market. Patient-facing devices...

Many of the dominant pharmaceutical companies operate partly, or wholly, in the generic drugs market. In 2016, the generics divisions of Teva, Mylan and Novartis all reported revenues in excess of $9bn with the top ten manufacturers...

The rising cost of clinical trials (CTs), coupled with the commercial risks of failure, mean it’s increasingly important to harness the power of real-world data to inform effective trial designs, better understand outcomes and maximise the likelihood of clinical success...

Elpenhaler® is ELPEN’s propriety classic DPI device, developed to administer various medications for the treatment of asthma and COPD (Figure 1). Each dose of medication is packed into the blister of an alu-alu strip..

Connected drug delivery products (Drug delivery devices with attached/incorporated capability that includes connectivity to wider digital services) continue to be a driving force in medical devices. In this whitepaper...

Low adherence to therapy is a recognized issue in respiratory disease and has driven the development of electronic sensors for monitoring inhaler use. To date, sensors for dry powder inhalers (DPIs) have...

“What does the youngest chief executive in Big Pharma want? A control room straight off the starship Enterprise.”… That was the headline of a recent Forbes article on the vision of the new Novartis CEO, Vasant Narsimhan...

The era of clinical trials as we’ve known them, is coming to an end. Rising costs, coupled with the commercial risks of failure, are unsustainable. This disruptive state is driving the adoption of new technologies, and catalysing...

There is a need for more clinical trials across more sites. The need will continue to grow. This increase comes at a significant cost. Costs can be managed it we tack inefficiencies. digital technologies could reduce trial costs...

I’ve just got back to the office from a very interesting workshop looking to address the challenge of delivering rapid microbial testing in cell and gene products...